Current Report Filing (8-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

October 1, 2015

Date of Report (Date of earliest event reported)

Immune Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Florida		000-54933		59-3226705
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.

37 North Orange Ave, Suite 607, Orlando, FL		32801
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code 888-613-8802

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On October 7, 2015, the Company issued a press release in the form attached hereto as Exhibit 8.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibits are filed herewith.

Exhibit No.		Description

8.1		Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMMUNE THERAPEUTICS, INC.

Date: October 7, 2015	By:	/s/ Noreen Griffin
		Noreen Griffin, CEO

Exhibit 8.1

Immune Therapeutics Inc. Provides Update on Clinical Trial of Lodonal as an Immune-System Regulating Agent in Subjects with Compromised Immune Systems

Orlando, Florida -- Immune Therapeutics Inc. a specialty biopharmaceutical company (OTCQB: IMUN) today provided an update on the ongoing clinical trial of Lodonal in Nigeria.

The trial is an open-label, placebo-controlled study that includes a 90-day treatment period followed by a 60-day extension. The primary objective of this clinical trial is to confirm that Lodonal has a beneficial effect on the immune system of patients in Nigeria with a compromised immune system (refer to Inclusion/Exclusion Criteria). This will be determined by: the number of subjects on Lodonal who achieve CD4 count stabilization (less than 10% change from baseline mean values) or a 25% increase in CD4 counts when compared to the observation group from baseline to Days 30, 60 and 90.

Noreen Griffin, Chief Executive Officer of Immune Therapeutics, commented, "We are pleased to have completed 100% enrollment, but due to unforeseen delays, the anticipated results will not be available until approval of the results by Nigerian National Agency for Food and Drug Administration and Control, targeted for Q-1, 2016.”

Dr. Afonja, co-principal investigator for this study stated, "We are looking forward to the results of this bridging study given what it could mean for AIDS patients in Nigeria, and possibly in other developing African nations given the prevalence of AIDS patients in these populations.”

Forward Looking Statements

This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by Immune Therapeutics may not proceed as contemplated, and by all other matters specified in Immune Therapeutic’s filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. Immune Therapeutics does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Immune Therapeutic’s filings with the Securities and Exchange Commission, including its recent periodic reports.

About Immune Therapeutics, Inc.:

Immune Therapeutics Inc [formally TNI Biotech, name change 2014] is a biotechnology company working to combat chronic, life-threatening diseases through the activation and

modulation of the body’s immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.

About TNI BioTech International, Ltd.:

TNI BioTech International, Ltd., a wholly owned subsidiary of Immune Therapeutics, Inc. incorporated in the British Virgin Islands, is responsible for managing Immune Therapeutics’ international distribution and is the contracting entity for the Nigerian 90-Day Lodonal(TM) Bridging trial.

For more information please contact:

Mike King, Director, Princeton Research, Inc. 3887 Pacific St Las Vegas, NV 89121 Office: (702) 650-3000 Web: www.princetonresearch.com FB: www.facebook.com/princetonresearch

Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Jun 2024 to Jul 2024